Scinai Immunotherapeutics (SCNI) Cash from Investing Activities (2018 - 2024)
Scinai Immunotherapeutics' (SCNI) quarterly Cash from Investing Activities came in at -$4000.0 in Q3 2024, up 80.0% year-on-year from -$2222.2 in Q4 2023, and up 33.33% quarter-over-quarter from -$6000.0 in Q2 2024.
Scinai Immunotherapeutics (SCNI) Cash from Investing Activities (2018 - 2024) Analysis & Trends
Scinai Immunotherapeutics has disclosed Cash from Investing Activities across 7 years of filings, most recently posting -$4000.0 for Q3 2024.
- Cash from Investing Activities for Q3 2024 came in at -$4000.0, up 80.0% year-over-year; the trailing twelve-month figure through Dec 2024 was -$12000.0 (up 98.12% YoY), and the FY2025 annual result was -$24000.0, down 100.0% from the prior year.
- Cash from Investing Activities came in at -$4000.0 for Q3 2024 at Scinai Immunotherapeutics, up from -$6000.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $321000.0 in Q4 2020 to a low of -$3.3 million in Q3 2020.
- The 5-year median for Cash from Investing Activities is -$82000.0 (2022), against an average of -$342222.2.
- Across the five-year window, Cash from Investing Activities jumped 132.39% in 2020 and tumbled 13125.0% in 2022, its largest moves.
- Scinai Immunotherapeutics' Cash from Investing Activities stood at $321000.0 in 2020, then tumbled by 133.02% to -$106000.0 in 2021, then tumbled by 154.72% to -$270000.0 in 2022, then grew by 13.33% to -$234000.0 in 2023, then jumped by 98.29% to -$4000.0 in 2024.
- The last three Cash from Investing Activities figures came in at -$4000.0 (Q3 2024), -$6000.0 (Q2 2024), and -$2000.0 (Q1 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 579,519.10 |
| 10 | Scinai Immunotherapeutics | 3.02 Bn | 988.23 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | -4,000.00 |
| Sep 30, 2024 | -4,000.00 |
| Jun 30, 2024 | -6,000.00 |
| Jun 30, 2024 | -6,000.00 |
| Mar 31, 2024 | -2,000.00 |
| Mar 31, 2024 | -2,000.00 |
| Dec 31, 2023 | -234,000.00 |
| Dec 31, 2023 | -234,000.00 |
| Sep 30, 2023 | -20,000.00 |
| Sep 30, 2023 | -20,000.00 |
| Jun 30, 2023 | -377,000.00 |
| Jun 30, 2023 | -377,000.00 |
| Mar 31, 2023 | -6,000.00 |
| Mar 31, 2023 | -6,000.00 |
| Dec 31, 2022 | -270,000.00 |
| Dec 31, 2022 | -270,000.00 |
| Sep 30, 2022 | -80,000.00 |
| Sep 30, 2022 | -80,000.00 |
| Jun 30, 2022 | -84,000.00 |
| Jun 30, 2022 | -84,000.00 |